Literature DB >> 27298418

Association of Androgen Deprivation Therapy With Alzheimer's Disease: Unmeasured Confounders.

Jeffrey J Leow1, Alexander P Cole2, Maxine Sun2, Quoc-Dien Trinh3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27298418      PMCID： PMC5019755          DOI： 10.1200/JCO.2016.66.6594

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Patients Who Receive Androgen Deprivation Therapy Risk Adverse Cognitive Changes.

Authors:  Robert A Gardiner; John Yaxley; Kenneth I Pakenham; Heather Green; Peter Mactaggart; Roger Watson; Cheryl Swanson; David L Nicol
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544

2.  Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer.

Authors:  Shabbir M H Alibhai; Henriette Breunis; Narhari Timilshina; Shireen Marzouk; Diane Stewart; Ian Tannock; Gary Naglie; George Tomlinson; Neil Fleshner; Murray Krahn; Padraig Warde; Sarah Duff Canning
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

3.  Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Authors:  Arnold L Potosky; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Miao Jiang; Huei-Ting Tsai; George Luta; Nancy L Keating; Matthew R Smith; Stephen K Van Den Eeden
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

4.  Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Authors:  Maxine Sun; Toni K Choueiri; Ole-Petter R Hamnvik; Mark A Preston; Guillermo De Velasco; Wei Jiang; Stacy Loeb; Paul L Nguyen; Quoc-Dien Trinh
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

Review 5.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Authors:  D Andrew Loblaw; Katherine S Virgo; Robert Nam; Mark R Somerfield; Edgar Ben-Josef; David S Mendelson; Richard Middleton; Stewart A Sharp; Thomas J Smith; James Talcott; Maryellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

6.  Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.

Authors:  Brian D Gonzalez; Heather S L Jim; Margaret Booth-Jones; Brent J Small; Steven K Sutton; Hui-Yi Lin; Jong Y Park; Philippe E Spiess; Mayer N Fishman; Paul B Jacobsen
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

7.  Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.

Authors:  Peter C Albertsen; Laurence Klotz; Bertrand Tombal; James Grady; Tine K Olesen; Jan Nilsson
Journal:  Eur Urol       Date:  2013-11-01       Impact factor: 20.096

8.  American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

Authors:  D Andrew Loblaw; David S Mendelson; James A Talcott; Katherine S Virgo; Mark R Somerfield; Edgar Ben-Josef; Richard Middleton; Henry Porterfield; Stewart A Sharp; Thomas J Smith; Mary Ellen Taplin; Nicholas J Vogelzang; James L Wade; Charles L Bennett; Howard I Scher
Journal:  J Clin Oncol       Date:  2004-06-07       Impact factor: 44.544

9.  Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.

Authors:  Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

10.  Sensitivity Analysis Without Assumptions.

Authors:  Peng Ding; Tyler J VanderWeele
Journal:  Epidemiology       Date:  2016-05       Impact factor: 4.822
  10 in total
  2 in total

1.  Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al.

Authors:  Kevin T Nead; Greg Gaskin; Cariad Chester; Samuel Swisher-McClure; Joel T Dudley; Nicholas J Leeper; Nigam H Shah
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544

2.  Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.

Authors:  Gregory L Branigan; Georgina Torrandell-Haro; Maira Soto; Edward P Gelmann; Francesca Vitali; Kathleen E Rodgers; Roberta Diaz Brinton
Journal:  Cancer Med       Date:  2022-03-16       Impact factor: 4.711
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.